FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke

BMJ. 2005 Feb 26;330(7489):440. doi: 10.1136/bmj.330.7489.440.
No abstract available

Publication types

  • News

MeSH terms

  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / adverse effects*
  • Humans
  • Lactones / adverse effects
  • Membrane Proteins
  • Myocardial Infarction / chemically induced*
  • Prostaglandin-Endoperoxide Synthases*
  • Risk Factors
  • Stroke / chemically induced*
  • Sulfones / adverse effects
  • United States
  • United States Food and Drug Administration

Substances

  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Lactones
  • Membrane Proteins
  • Sulfones
  • rofecoxib
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases